(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...
R21/Matrix-M booster maintains high efficacy against first and multiple episodes of clinical malaria
The phase 1/2b clinical trial on R21/Matrix-M malaria vaccine has recently reported the safety and efficacy of booster vaccination at 12 months. The entire report has been published in The Lancet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback